Lipid profile and cardiovascular risk factors in pediatric liver transplant recipients
Emilie Roblin
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorCorresponding Author
Jérôme Dumortier
Unité de Transplantation hépatique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Université Claude Bernard Lyon 1, Lyon, France
Jérôme Dumortier, MD, PhD, Pavillon Hbis, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France
Tel.: 33 4 72 11 01 11
Fax: 33 4 72 11 01 47
E-mail: [email protected]
Search for more papers by this authorMathilde Di Filippo
UF Dyslipidémies Cardiobiologie, Département de Biochimie et de Biologie Moléculaire du GHE, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Lyon, France
INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
Search for more papers by this authorSophie Collardeau-Frachon
Université Claude Bernard Lyon 1, Lyon, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorAgnès Sassolas
INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorNoël Peretti
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorAndré Serusclat
Service d'Imagerie, Hôpital Cardiovasculaire et pneumologique Louis Pradel, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorChristine Rivet
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorOlivier Boillot
Unité de Transplantation hépatique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Université Claude Bernard Lyon 1, Lyon, France
Search for more papers by this authorAlain Lachaux
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Université Claude Bernard Lyon 1, Lyon, France
Search for more papers by this authorEmilie Roblin
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorCorresponding Author
Jérôme Dumortier
Unité de Transplantation hépatique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Université Claude Bernard Lyon 1, Lyon, France
Jérôme Dumortier, MD, PhD, Pavillon Hbis, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France
Tel.: 33 4 72 11 01 11
Fax: 33 4 72 11 01 47
E-mail: [email protected]
Search for more papers by this authorMathilde Di Filippo
UF Dyslipidémies Cardiobiologie, Département de Biochimie et de Biologie Moléculaire du GHE, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Lyon, France
INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
Search for more papers by this authorSophie Collardeau-Frachon
Université Claude Bernard Lyon 1, Lyon, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorAgnès Sassolas
INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorNoël Peretti
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Service de Pathologie, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorAndré Serusclat
Service d'Imagerie, Hôpital Cardiovasculaire et pneumologique Louis Pradel, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorChristine Rivet
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorOlivier Boillot
Unité de Transplantation hépatique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Université Claude Bernard Lyon 1, Lyon, France
Search for more papers by this authorAlain Lachaux
Service d'Hépatologie, Gastroentérologie et Nutrition pédiatriques, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
Université Claude Bernard Lyon 1, Lyon, France
Search for more papers by this authorAbstract
Cardiovascular diseases induce long-term morbidity and mortality of adult LT recipients. The aim of this retrospective study was to assess CVRF, lipid abnormalities, and atherosclerosis (appraised by c-IMT), more than 10 yr after pediatric LT. Thirty-one children who underwent LT between December 1990 and December 2000 were included. Median age at LT was 14 months (range 4–64), and median follow-up after LT was 11.9 yr (range 9.0–17.3). In our cohort, obesity (9.7%) and treated hypertension (9.7%) were rare. None of the patients was smoker or diabetic. High TC and TG were both observed in 6.5% of the patients. The mean c-IMT for male patients was 1.22 ± 1.55 and 1.58 ± 1.23 mm in female patients. Seven patients (22%) had a mean c-IMT above +2 s.d. Values below the 5th percentile were noted for LDL-cholesterol (58.1%), HDL-cholesterol (25.8%), apolipoprotein B (40%), and apolipoprotein A1 (20%). LDL-cholesterol and apolipoprotein B levels were significantly lower in patients treated by tacrolimus in comparison with CsA (p < 0.05). In conclusion, our results suggest that pediatric LT patients do not present significant CVRF; moreover, instead of hyperlipidemia, hypocholesterolemia (LDL-C) is frequent and immunosuppressive therapy is probably the cause.
References
- 1Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002: 73: 901–906.
- 2Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease–major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995: 60: 451–457.
- 3Mullins PA, Cary NR, Sharples L, et al. Coronary occlusive disease and late graft failure after cardiac transplantation. Br Heart J 1992: 68: 260–265.
- 4Fernandez-Miranda C, Sanz M, Dela Calle A, et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002: 15: 556–562.
- 5Guckelberger O, Byram A, Klupp J, et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005: 18: 967–974.
- 6Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995: 60: 1057–1060.
- 7Borg MA, van der Wouden EJ, Sluiter WJ, Slooff MJ, Haagsma EB, van den Berg AP. Vascular events after liver transplantation: A long-term follow-up study. Transpl Int 2008: 21: 74–80.
- 8Basiratnia M, Fazel M, Lotfi M, et al. Subclinical atherosclerosis and related risk factors in renal transplant recipients. Pediatr Nephrol 2010: 25: 343–348.
- 9Dalla Pozza R, Urschel S, Bechtold S, Kozlik-Feldmann R, Schmitz C, Netz H. Subclinical atherosclerosis after heart and heart-lung transplantation in childhood. Pediatr Transplant 2008: 12: 577–581.
- 10Jarvisalo MJ, Jartti L, Nanto-Salonen K, et al. Increased aortic intima-media thickness: A marker of preclinical atherosclerosis in high-risk children. Circulation 2001: 104: 2943–2947.
- 11Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: A prospective study. Lancet 2001: 358: 1400–1404.
- 12LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990: 81: 1721–1733.
- 13Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997: 63: 331–338.
- 14Siirtola A, Antikainen M, Ala-Houhala M, et al. Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation. Transpl Int 2004: 17: 109–119.
- 15Steinberger J, Daniels SR, Eckel RH, et al. Progress and challenges in metabolic syndrome in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009: 119: 628–647.
- 16Jourdan C, Wuhl E, Litwin M, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 2005: 23: 1707–1715.
- 17Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005: 41: 1313–1321.
- 18Rolland-Cachera MF. Childhood obesity: Current definitions and recommendations for their use. Int J Pediatr Obes 2011: 6: 325–331.
- 19http://www.agence-biomedecine.fr/annexes/bilan2013/donnees/organes/09-pediatrie/synthese.htm.
- 20Markiewicz-Kijewska M, Kalicinski P, Kluge P, et al. Immunological factors and liver fibrosis in pediatric liver transplant recipients. Ann Transplant 2015: 20: 279–284.
- 21Narkewicz MR, Green M, Dunn S, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: Report of the studies of pediatric liver transplantation experience. Liver Transpl 2013: 19: 730–740.
- 22Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. Liver Transpl 2008: 14: 1648–1654.
- 23Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events. Liver Transpl 2007: 13: 1109–1114.
- 24Kosola S, Lampela H, Makisalo H, et al. Metabolic syndrome after pediatric liver transplantation. Liver Transpl 2014: 20: 1185–1192.
- 25Brzosko S, Lebkowska U, Malyszko J, Hryszko T, Pawlak K, Mysliwiec M. Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients. Clin Transplant 2001: 15: 349–353.
- 26Becker J, Huber WD, Aufricht C. Short- and long-time effects of pediatric liver transplantation on serum cholesterol and triglyceride levels–the Vienna cohort. Pediatr Transplant 2008: 12: 883–888.
- 27Fernandez-Miranda C, Guijarro C, de la Calle A, et al. Lipid abnormalities in stable liver transplant recipients–effects of cyclosporin, tacrolimus, and steroids. Transpl Int 1998: 11: 137–142.
- 28de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988: 63: 1012–1021.
- 29McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998: 65: 87–92.
- 30Tory R, Sachs-Barrable K, Goshko CB, Hill JS, Wasan KM. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Transplantation 2009: 88: 62–68.
- 31Kosola S, Lampela H, Gylling H, et al. Cholesterol metabolism altered and FGF21 levels high after pediatric liver transplantation despite normal serum lipids. Am J Transplant 2012: 12: 2815–2824.
- 32Perito ER, Glidden D, Roberts JP, Rosenthal P. Overweight and obesity in pediatric liver transplant recipients: Prevalence and predictors before and after transplant, United Network for Organ Sharing Data, 1987-2010. Pediatr Transplant 2012: 16: 41–49.
- 33Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008: 40: 521–527.
- 34Seymen P, Yildiz M, Turkmen MF, Titiz MI, Seymen HO. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. Transplant Proc 2009: 41: 4181–4183.
- 35Tarantino G, Palmiero G, Polichetti G, et al. Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. Int J Immunopathol Pharmacol 2010: 23: 1303–1308.
- 36Di Filippo M, Moulin P, Roy P, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 2014: 61: 891–902.
- 37Heeks LV, Hooper AJ, Adams LA, et al. Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. Clin Chim Acta 2013: 421: 121–125.
- 38Harada N, Soejima Y, Taketomi A, et al. Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation. Liver Transpl 2009: 15: 806–809.
- 39Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989: 9: I19–I32.
- 40Hyams JS, Treem WR, Andrews WS, Herbert PN. Lipid abnormalities in pediatric hepatic allograft recipients. J Pediatr Gastroenterol Nutr 1989: 9: 441–444.
- 41Siirtola A, Solakivi T, Jokela H, et al. Hypertriglyceridemia and low serum HDL cholesterol are common in children after liver transplantation. Transplant Proc 2001: 33: 2449.
- 42Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010: 31: 2844–2853.
- 43Couderc R, Maachi M. Lipoprotein (a), a cardiovascular risk factor: Importance of its determination in current clinical practice. J Mal Vasc 1998: 23: 165–175.
- 44Goldenberg NA, Bernard TJ, Hillhouse J, et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica 2013: 98: 802–807.
- 45Strater R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood–a 5-year follow-up study. Lancet 2002: 360: 1540–1545.
- 46Romero F, Rodriguez-Iturbe B, Pons H, et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000: 152: 127–133.
- 47Misra S, Moore TB, Ament ME, Vargas JH, Busutill RW, McDiarmid SV. Profile of anemia in children after liver transplantation. Transplantation 2000: 70: 1459–1463.
- 48Atac B, Brahaj D, Frishman WH, Lerner R. Anemia and hypocholesterolemia. Heart Dis 2003: 5: 65–71.
Citing Literature
